drugset / Trial / NCT05938270

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

NCT05938270

Phase 1 Completed 113 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelBasic science

Summary

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

Timeline

Start
2023-09-21
Primary completion
2026-06-15
Completion
2026-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Darolutamide Other / unclassified 1200 mg Oral
Subject Saruparib Small molecule Oral

Indications